Results showed that BP were involved in PF treatment (Figure 4(a)), including positive regulation of transcription from RNA polymerase II promoter, inflammatory response, and signal transduction, etc. Concerning prediction of KEGG by David 6.8, the results revealed that most of the therapeutic targets are associated with signal transduction (e.g., MAPK signaling pathway and PI3K-protein kinase B (Akt) signaling pathway), inflammation (e.g., TNF signaling pathway and HIF-1 signaling pathway), and immune response (e.g., toll-like receptor signaling pathway and Jak-STAT signaling pathway). This evidence concerns the gene SOAT1 and pemphigus foliaceus.